Salman Fariha, Oktaei Hooman, Solomon Solomon, Nyenwe Ebenezer
Division of Endocrinology, Diabetes and Metabolism, University of Tennessee Health Science Center, Memphis, TN, USA.
Division of Endocrinology, Diabetes and Metabolism, University of Tennessee Health Science Center, 920 Madison Ave, Suite 300A, Memphis TN 38163, USA.
Ther Adv Endocrinol Metab. 2017 Jul;8(7):111-115. doi: 10.1177/2042018817730278. Epub 2017 Sep 12.
Radioactive iodine (RAI) is the most cost effective therapy for Graves' disease (GD). Patients with GD who have become hypothyroid after therapeutic RAI, rarely develop recurrence of disease. Herein we describe a case of recurrence of thyrotoxicosis after 2 years of hypothyroidism.
We present the clinical features, laboratory findings, imaging and management of an unusual case of recurrent hyperthyroidism.
A 48-year-old male presented to the emergency room with a 2-day history of palpitation, chest discomfort and 30 pounds of weight loss. Examination was remarkable for rapid and irregular pulse, diffuse thyromegaly and brisk deep tendon reflexes but no eye changes or tremors. Laboratory tests showed thyroid-stimulating hormone (TSH) of <0.004 (0.3-5.6 mIU/ml), free thyroxine (FT4) 4.96 (0.9-1.8 ng/dl), free triiodothyronine (FT3) >20 (1.8-4.7 pg/ml), total thyroxine >800 (80-200 ng/dl). Electrocardiogram showed atrial fibrillation with rapid ventricular response. RAI uptake and scan showed a homogenous gland with 54% uptake in 6 h and 45% in 24 h. He was treated with propranolol and propylthiouracil with some clinical improvement. He subsequently underwent RAI therapy and developed hypothyroidism after 8 weeks. Hypothyroidism was treated with levothyroxine. At 2 years after RAI ablation, he again developed symptoms of hyperthyroidism and had suppressed TSH. The levothyroxine dose was stopped, 3 weeks after discontinuing levothyroxine, he remained hyperthyroid with TSH of 0.008 and FT4 of 1.62 and FT3 of 4.8. RAI uptake demonstrated 17% uptake at 24 h.
Recurrent hyperthyroidism in GD is uncommon after development of post-ablative hypothyroidism. Our case illustrates the need for continued surveillance.
放射性碘(RAI)是治疗格雷夫斯病(GD)最具成本效益的疗法。接受治疗性RAI后发生甲状腺功能减退的GD患者很少出现疾病复发。在此,我们描述一例甲状腺功能减退2年后甲状腺毒症复发的病例。
我们介绍了一例复发性甲状腺功能亢进症罕见病例的临床特征、实验室检查结果、影像学检查及治疗情况。
一名48岁男性因心悸、胸部不适2天及体重减轻30磅就诊于急诊室。检查发现脉搏快速且不规则、甲状腺弥漫性肿大、深腱反射亢进,但无眼部改变或震颤。实验室检查显示促甲状腺激素(TSH)<0.004(0.3 - 5.6 mIU/ml),游离甲状腺素(FT4)4.96(0.9 - 1.8 ng/dl),游离三碘甲状腺原氨酸(FT3)>20(1.8 - 4.7 pg/ml),总甲状腺素>800(80 - 200 ng/dl)。心电图显示心房颤动伴快速心室反应。RAI摄取和扫描显示甲状腺均匀,6小时摄取率为54%,24小时摄取率为45%。他接受了普萘洛尔和丙硫氧嘧啶治疗,临床症状有所改善。随后他接受了RAI治疗,8周后出现甲状腺功能减退。甲状腺功能减退用左甲状腺素治疗。RAI消融术后两年,他再次出现甲状腺功能亢进症状,TSH被抑制。停用左甲状腺素3周后,左甲状腺素剂量停止,他仍处于甲状腺功能亢进状态,TSH为0.008,FT4为1.62,FT3为4.8。RAI摄取显示24小时摄取率为17%。
GD患者在消融后发生甲状腺功能减退后复发性甲状腺功能亢进并不常见。我们的病例表明需要持续监测。